The characteristic phenotype is defined by the combination of several surface markers (CD5, CD19, CD20, and CD23), and the Royal Marsden Hospital (RMH) score is widely used to distinguish CLL from other B-cell chronic lymphoproliferative disorders (B-CLPD) [1]. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.